Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223469 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19GRM4L3MBTL1 | |
| SCHEMBL8102792 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL9447193 | 0.83 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19GRM4L3MBTL1 | |
| SCHEMBL30368161 | 0.82 | GRM4 (0.59) | CYP1A2CYP2C9CYP2C19GRM4LMNA | |
| SCHEMBL344357 | 0.82 | L3MBTL1 (0.64) | L3MBTL1MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL7426198 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL344338 | 0.81 | GRM4 (0.57) | CYP1A2CYP2C9CYP2C19GRM4L3MBTL1 | |
| SCHEMBL9430586 | 0.80 | KDM4E (0.55) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL9430839 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL28684668 | 0.79 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2021239133-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | 南京正大天晴制药有限公司 | 2021-12-02 | — | — | WO | disclosed |
| EP-2443108-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | Ferrer Internacional, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20120088809-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-12 | — | — | US | disclosed |
| US-20120088809-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-12 | — | — | US | disclosed |
| WO-2011070299-A1 | TRI-SUBSTITUTED 9H-BETA-CARBOLINE (OR 9H-PYRIDO[3,4-B]INDOLE) DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070299-A1 | TRI-SUBSTITUTED 9H-BETA-CARBOLINE (OR 9H-PYRIDO[3,4-B]INDOLE) DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | WO | disclosed |
| EP-2266975-A1 | 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds | Ferrer Internacional, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266975-A1 | 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds | Ferrer Internacional, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010145989-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145989-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2010-12-23 | — | — | WO | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088809-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | MTNR1A, MTNR1B, TPH2 | CYP1A2 328/4885CYP2C9 2737/4885CYP2C19 1065/4885 |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | CYP1A2 538/4885CYP2C9 695/4885CYP2C19 395/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | CYP1A2 3670/4885CYP2C9 2726/4885CYP2C19 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.